Core Viewpoint - Bio-Techne Corporation has entered into an agreement for Mdxhealth SA to acquire its Exosome Diagnostics Inc. business, which includes the ExoDx Prostate (EPI) test and a CLIA-certified clinical laboratory, while Bio-Techne retains access to the proprietary exosome-based technology for future kit development [1][2]. Group 1: Transaction Details - Mdxhealth is seen as an ideal acquirer for the ExoDx Prostate test and laboratory, enhancing its leadership in urology and prostate cancer diagnostics [2]. - Bio-Techne will receive $5 million in MDXH stock along with future considerations as part of the transaction, expected to close in the first quarter of Bio-Techne's fiscal 2026 [2]. Group 2: Strategic Implications - The acquisition allows Bio-Techne to focus on developing high-value, high-margin products for life science research and clinical diagnostics, thereby improving its operating margin profile [2]. - Mdxhealth views the ExoDx Prostate test as a strategic fit that will help men make informed decisions regarding prostate biopsies, building on Bio-Techne's success in delivering this information [2]. Group 3: Company Background - Bio-Techne Corporation is a global life sciences company with approximately $1.2 billion in net sales for fiscal 2024 and over 3,000 employees worldwide, providing innovative tools and bioactive reagents for research and clinical diagnostics [6]. - Mdxhealth specializes in precision diagnostics for cancer, utilizing proprietary genetic and molecular technologies to assist in the diagnosis and prognosis of urologic cancers [7].

Core Insights - Sidra Medicine has been awarded a $100,000 G-Rex® Grant to develop a CAR-T cell production platform focused on pediatric oncology [1][2] - The grant will facilitate the preclinical development of a CD19 CAR-T cell therapy product and support the implementation of a fully closed system, semi-automated G-Rex production compliant with current Good Manufacturing Practices (cGMPs) [2][3] - ScaleReady's G-Rex Grant Program has committed over $40 million to advance cell and gene-modified cell therapy (CGT) development and manufacturing [5] Company Developments - Sidra Medicine aims to enhance treatment protocols for pediatric diseases, leveraging the G-Rex® method for efficient T cell manufacturing [3][4] - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials [8] - ScaleReady has introduced a new program, LEAN Cell & Gene™, to help CGT entities improve operational efficiency and product quality [6] Industry Context - The G-Rex centric manufacturing process offers significant technical and economic advantages for CAR-T manufacturing in Qatar and the Middle East [4] - The G-Rex Grant recipients gain access to exclusive support from ScaleReady's consortium, enhancing their capabilities in cGMP manufacturing and regulatory affairs [5][9] - Bio-Techne Corporation collaborates with Wilson Wolf to provide tailored products for G-Rex® Bioreactors, supporting high throughput closed-system manufacturing [11]

Core Insights - Bio-Techne Corporation (TECH) is scheduled to release its fourth-quarter fiscal 2025 results on August 6, before market opening [1] - The company reported adjusted earnings per share (EPS) of 56 cents in the last quarter, exceeding the Zacks Consensus Estimate by 9.8%, with an average surprise of 6.74% over the past four quarters [1][3] Q4 Estimates for TECH - The Zacks Consensus Estimate for Bio-Techne's revenues is $317.4 million, reflecting a 3.7% increase from the previous year [2] - The EPS estimate suggests a 2% year-over-year improvement to 50 cents [2] Estimate Revision Trend - Earnings estimates for the fourth quarter have remained stable at 50 cents over the past 60 days [3] Factors Impacting Performance - Management noted macro uncertainties, including tariffs and potential NIH budget cuts, which could temporarily slow growth momentum in Q4 [4] - The Protein Sciences division accounted for 72% of net sales in Q3, with potential modest impacts from the divestment of the fetal bovine serum business [5] Growth Drivers - Bio-Techne is expected to benefit from strong demand for research reagents, protein analysis tools, and cell therapy workflow solutions [6] - The FDA's shift away from animal testing may enhance growth for Bio-Techne's organoid solutions, providing ethical and cost-effective alternatives [7] - The protein analytical instrumentation business, particularly the Maurice platform, is anticipated to show strong momentum [8][9] Segment Performance - The Biologics segment's revenue estimate is $225 million, up 5.1% from the previous year, driven by instrument placements and consumables [9] - The Spatial Biology segment is expected to generate $93 million in revenue, a 2.2% increase year-over-year, despite facing NIH funding uncertainties [12] Earnings ESP and Zacks Rank - Bio-Techne has an Earnings ESP of 0.00%, indicating no expected earnings surprise [13] - The company currently holds a Zacks Rank of 4 (Sell) [13]

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced the awarding of $665,000 in G-Rex Grant funding to three investigators at the University of Minnesota's Center for Genome Engineering [1] Funding Details - Dr. Branden Moriarity received a $300,000 G-Rex Grant for a novel hyper-functional CAR NK cell therapy targeting advanced epithelial ovarian cancer in a Phase 1 clinical trial [2] - Dr. Beau Webber was awarded $240,000 for preclinical development of a novel TIL therapy for various solid tumors [3] - Dr. Joseph Skeate received $125,000 to support process development for TPP1 expressing T cells therapy for Batten Disease [4] Industry Impact - The G-Rex Grant Program has surpassed $40 million in no-cost product commitments aimed at advancing cell and gene-modified cell therapy development and manufacturing [7] - ScaleReady's G-Rex manufacturing platform is utilized by over 800 organizations, producing drug products for approximately 50% of CGT clinical trials and five commercially approved CGT drugs [10] Additional Initiatives - ScaleReady introduced a free program called LEAN Cell & Gene™ to help CGT entities improve efficiency and quality in manufacturing [8]

Group 1 - Bio-Techne Corporation is the market leader in high-quality biological reagents used in the life science market [1] - The company specializes in manufacturing high-quality proteins, antibodies, and immunoassays [1] - Long-term growth in cell biology is expected to benefit the company [1]

Core Viewpoint - Bio-Techne Corporation will host a conference call and webcast to review its fourth quarter and fiscal 2025 financial results on August 6, 2025 [1] Group 1: Conference Call Details - The conference call is scheduled for 8:00 a.m. CDT on August 6, 2025 [1] - Dial-in numbers are provided for both domestic (1-800-274-8461) and international callers (1-203-518-9814) [1] - A recorded rebroadcast will be available from 11:00 a.m. CDT on August 6, 2025, until 11:00 p.m. CDT on September 6, 2025 [2] Group 2: Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [3] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [3] - Bio-Techne's products support scientific investigations into biological processes and aid in drug discovery and clinical testing [3]

Core Insights - Investors in the Medical - Biomedical and Genetics sector may consider Incyte (INCY) and Techne (TECH) for potential value investments [1] Valuation Metrics - Incyte has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Techne has a Zacks Rank of 4 (Sell) [3] - Incyte's forward P/E ratio is 11.80, significantly lower than Techne's forward P/E of 24.67, suggesting that Incyte may be undervalued [5] - Incyte's PEG ratio is 0.47, compared to Techne's PEG ratio of 2.17, indicating better expected earnings growth relative to its valuation [5] - Incyte has a P/B ratio of 3.6, while Techne's P/B ratio is 4.03, further supporting Incyte's valuation attractiveness [6] - Incyte's overall Value grade is A, while Techne's Value grade is C, highlighting Incyte's superior valuation metrics [6] Earnings Outlook - Incyte is noted for its improving earnings outlook, which enhances its attractiveness as a value investment compared to Techne [7]

Core Insights - American Trust Investment Services, Inc. (ATIS) successfully executed the initial public offering (IPO) of K-TECH Solutions Co., Ltd. on Nasdaq, marking a significant achievement in capital markets [1][5] - The IPO involved the offering of 1,600,000 ordinary shares at a price of $4.00 per share, generating gross proceeds of $6.4 million before any discounts and expenses [2] - K-TECH Solutions specializes in educational toys and learning kits, with a diverse product range serving customers in North America, Europe, and other markets [3] Financial Details - The offering generated gross proceeds of $6.4 million, with an additional 240,000 shares available for purchase by the underwriter to cover over-allotments [2] - The net proceeds from the offering will be allocated for product development, production capacity expansion, and general corporate purposes [4] Company Background - ATIS is a leading investment bank providing tailored capital markets solutions for both emerging and established companies, with a strong focus on IPOs and follow-on offerings [6] - The firm is recognized for its hands-on approach and extensive experience in guiding businesses through complex financial transactions [6]

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and ...

Core Insights - Bio-Techne Corporation's Simple Western™ Technology was instrumental in the FDA approval of ZEVASKYN™, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) developed by Abeona Therapeutics [1][5] - ZEVASKYN addresses a significant unmet medical need for RDEB patients, who previously had no durable therapies available [3][8] Company Overview - Bio-Techne Corporation is a global life sciences company that generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [6] - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being its flagship product [8] Technology and Methodology - Simple Western was chosen by Abeona for its speed, reproducibility, sensitivity at picogram levels, and minimal sample volume requirements, effectively detecting both trimeric and monomeric forms of Collagen VII [2][4] - The platform provided GMP-compliant data to ensure consistency across ZEVASKYN product lots, overcoming challenges in analytical standardization and complex assay development [4] Clinical Significance - RDEB is a rare genetic skin disorder caused by mutations in the COL7A1 gene, leading to severe symptoms and increased risk of life-threatening complications [3] - The approval of ZEVASKYN marks a significant milestone in the field of cell-based gene therapy, providing a new treatment option for RDEB patients [5]